Key Takeaways
- Custom Synthesis mix hit 60%, lifting margins: The higher-value CS share drove gross margin to ~68%, but management warned this is lumpy and the full-year margin should land near last year's ~60%.
- Inventory build is deliberate, not a demand miss: A ~₹500 crore inventory increase reflects a 3-month raw material buffer against supply-chain disruption and validation batches for new capex, not unsold finished goods.
- Double-digit growth commitment reaffirmed: Management reiterated the full-year growth pledge "no matter what," with commercial volumes from new generics and contrast media expected in the coming quarters.
- Generic pricing relief is cost pass-through, not structural: The observed price inflection is a market correction from higher raw material costs, not an easing of competitive intensity; Divi's raised prices only to maintain viability.
- What to watch next quarter: The pace of customer qualifications on the 4 filed generic DMFs, the start of substantial contrast media shipments to the second customer, and whether the CS mix normalizes downward as guided.
Custom Synthesis & the Mix Shift
- CS revenue share rose to 60% of standalone revenue, a higher share than in some prior quarters, and was the direct driver of the quarter's margin uplift.
- Lumpiness is the rule: Management stressed that quarterly CS/Generics mix swings are normal and unpredictable, driven by customer order timing and regulatory approval cadences. The full-year gross margin is expected to be comparable to or slightly better than last year's ~60%.
- Validation pipeline is deep but opaque: Several projects are in clinical studies, pre-validation, or validation stages. Some will not require large investments and can use existing facilities. Management declined to disclose phase-wise splits or molecule counts, citing confidentiality agreements.
- Regulatory gate: If approvals for validated projects come faster, the CS ratio rises as commercial volumes begin. For a new site like Kakinada, FDA approval may take 1–2 years, making the timeline a key swing factor.
Nilima Prasad Divi: "Let's not look at it on an individual quarter basis. Rather, we look at it on a year basis, where sometimes there's a lumpiness in one quarter and there is not so much of a custom synthesis business, but more of a generic business in another quarter."
Capex Commercialisation: The Three Big Bets
- Three major capex programmes are nearing completion with validations underway. Management confirmed these are for three different products, but declined to disclose end-market molecules, capacity, or the ratio of validation to eventual commercial volumes, citing CDAs.
- Contrast Media – Iodine has begun commercialisation with one customer, and long-term, multi-year contracts are being signed with two. The second customer is expected to start receiving substantial quantities in the next few months.
- Contrast Media – Gadolinium remains in a slow Phase II/III clinical qualification stage, waiting for customer regulatory approvals before advancing to Phase III.
- Generic DMFs — 4 filed in the last few years with various customers; validation quantities supplied and qualifications are underway. Commercial volumes expected in the next 3–6 months, with one customer negotiating long-term exclusivity. Products mentioned include Brivaracetam and Ticagrelor.
- Unit-3 (Kakinada) is currently absorbing pre-chemistry work from existing regulatory-approved plants to free up capacity. The long-term plan is full regulatory qualification, but the timeline depends on agency actions.
Dr. Kiran S. Divi: "I wish to share more, but I'm bound by CDAs not to share. All I can say is the validations have been completed, and we would be going commercial as and when the qualifications with the agencies are completed."
Peptides: The Next Leg of the Story
- Capacity expansion underway: Additional 3,000-litre SPPS (solid-phase peptide synthesis) systems are being installed to expand capacity, adding to existing infrastructure.
- Backward integration as the moat: Divi's manufactures its own protected amino acids, resins, FMOC/BOC-protected amino acids, dipeptides, tripeptides, fragments, and tags in-house. Management claims this is a unique, full-chain capability that provides a competitive edge on supply speed and cost.
- Pipeline progressing: Multiple peptide opportunities are in the pipeline, some in clinical phases and some undergoing validations. Qualification and validation activities for several peptide fragments are expected to advance over the coming quarters.
- Stated ambition: Divi's aims to be the largest integrated player in peptides globally.
Dr. Kiran S. Divi: "I think we are the only ones who start from basic raw materials, build our own peptide building blocks... we have a complete chain of backward integration, which gives us a much more better opportunity compared to others."
Generic Business & Pricing Dynamics
- Volumes stable, pricing competitive: Generic volumes held steady, but pricing continues to reflect competitive market conditions across products and geographies.
- The pricing inflection is a mirage: The observed positive move in generic API export pricing is a market correction driven by pass-through of higher raw material costs, not a reduction in underlying competitive intensity. Divi's has increased prices slightly wherever possible solely to maintain viability.
- Solvent costs are the villain: Solvent prices nearly doubled or tripled, driven by the Middle East situation, and some solvent-based raw materials also increased substantially. This cost pressure was partially offset by INR depreciation.
- Nutraceutical growth: The segment grew to ₹298 crores from ₹250 crores YoY, marking 20 years with a portfolio that has expanded from 2 products to over 100 offerings.
Dr. Kiran S. Divi: "Whatever you're seeing right now is a market correction based on the raw material prices that have taken a substantial hit. It's not based on the markets have corrected and the pricing pressure has gone down."
Supply Chain, Costs & the Inventory Bet
- The ~₹500 crore inventory build has two drivers: a conscious decision to stock raw materials on a 3-month rolling basis to prevent production stoppages or shipment delays, and new capex projects moving into validation batches with those materials reflected in inventory.
- The buffer worked: The 3-month rolling inventory strategy ensured no production loss or shipment stoppage in recent months despite West Asia disruption, elevated freight rates, port congestion, container shortages, cargo rollovers, and extended transit times.
- Cost of resilience: Raw materials were secured at higher cost, and solvent costs remained elevated for a significant part of the period. Net material consumption stood at 31.2% of standalone revenue, reflecting the integrated manufacturing model and product mix.
- How long this lasts: The 3-month rolling inventory strategy will continue as long as macro uncertainty persists. If the Middle East situation normalizes, both costs and inventory volumes would decrease.
- Forex drag: A net forex loss of ₹7 crores in Q1 FY27 compared to a net gain of ₹39 crores in Q1 FY26, occurring despite INR depreciation tailwinds.
Competitive Positioning & the CDMO Pitch
- It is not a price war: Management pushed back on the idea that CDMO competition is primarily about pricing, arguing innovators prioritize sustainability, safety, EHS capabilities, effluent management, and employee healthcare systems.
- The integrated model is the differentiator: Divi's backward integration from basic raw materials through to APIs and peptides, combined with regulatory track record and supply reliability, forms the core of its CDMO value proposition.
- Disclosure constraints are real: Management repeatedly declined to quantify capacity, project pipelines, or competitive benchmarks, citing confidentiality agreements with innovator customers. This limits external verification of the growth narrative.
Dr. Kiran S. Divi: "It's not about pricing. It's not the only thing innovators look at. They look at sustainability, they look at safety issues. They look at your EHS capabilities, your effluent management system, your employee health care system."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Double-digit revenue growth | Full-year growth "no matter what" | FY27 |
| Full-year gross margin | Comparable to or slightly better than ~60% | FY27 |
| Full-year EBITDA margin | Similar to last year | FY27 |
| Generic DMF commercialisation | Commercial volumes from 4 filed DMFs begin | Next 3–6 months |
| Contrast Media – Iodine, second customer | Substantial quantities to begin shipping | Next few months |
| Inventory strategy | 3-month rolling buffer maintained | As long as macro uncertainty persists |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated total income | ₹3,144 cr, vs ₹2,529 cr in Q1 FY26 |
| Standalone total income | ₹3,037 cr, vs ₹2,476 cr in Q1 FY26 |
| Standalone constant-currency revenue growth | 10% YoY |
| Profit before tax (consolidated) | ₹1,180 cr, vs ₹733 cr in Q1 FY26 |
| Profit after tax (consolidated) | ₹902 cr, vs ₹545 cr in Q1 FY26 |
| Gross margin | Close to 68% for the quarter; management notes lumpiness and does not expect this level to be consistent throughout the year |
| Net material consumption | 31.2% of standalone revenue from operations |
| Net forex loss | ₹7 cr loss, vs net forex gain of ₹39 cr in Q1 FY26 |
| Custom Synthesis revenue share | 60% of standalone revenue |
| Generics revenue share | 40% of standalone revenue |
| Global nutraceutical revenue | ₹298 cr, vs ₹250 cr in Q1 FY26 and ~₹240 cr in Q4 FY26 |
| Exports share of standalone revenue | Approximately 90% |
| Europe and North America share of exports | 75% |
| Overall capacity utilization | 80–85% across all three units |
| Assets capitalized during the quarter | ₹451 cr |
| Capital work in progress | ₹2,034 cr as of June 30, 2026 |
| Cash and cash equivalents | ₹3,611 cr as of quarter-end |
| Trade receivables | ₹3,056 cr as of quarter-end |
| Inventory | ₹4,413 cr as of quarter-end |
| Change in inventory | ~₹500 cr for the quarter, vs ₹50–100 cr in prior quarters and ~₹300 cr for full year FY26; driven by 3-month rolling raw material stocking and validation batch production |
| Three major capex projects total outlay | ~₹2,000 cr, approximately 70% capitalized so far |
| Commercialized or near-commercialized Custom Synthesis projects | Close to 18–20 projects |